A new COVID variant, NB.1.8.1, linked to a surge in China, has been detected in the United States via international travelers ...

A new Covid variant, NB.1.8.1, is detected in US airports. The variant is driving a surge in cases across China. Cases are ...

Amgen is no exception to this dynamic. Although 2017's Tax Cuts and Jobs Act spurred the company to build a handful of new ...

Preliminary data from researchers in China suggest the NB.1.8.1 variant is not better at evading the immune system compared ...

Pfizer is paying $1.25 billion to join the PD-(L1)xVEGF bispecific race. | Pfizer is paying $1.25 billion to join the ...

A new COVID-19 variant, NB.1.8.1, linked to a surge in cases across China and parts of Asia, has now been detected in the ...

In this week’s edition of InnovationRx, we look at the FDA's new rules on Covid-19 vaccines, Novartis’s acquisition strategy, ...

China continues to be a source of innovation as Pfizer strikes biggest pact yet; HHS provides more info on Trump’s Most ...

Under terms of the deal, Pfizer will gain rights to develop, manufacture, and commercialize SSGJ-707 outside of China.

The pharma giant entered an exclusive agreement with the Chinese biotech to gain rights to a cancer bispecific drug candidate.

US drugmaker Pfizer said it would license an experimental cancer treatment from China's 3SBio Inc, paying $1.25 billion upfront and up to another $4.8 billion if developmental milestones are met.

Pfizer on Tuesday announced a cancer drug licensing deal with Chinese biotech 3SBio that includes a $1.25 billion upfront ...